Tourmaline Bio Stock Price, News & Analysis

Tourmaline Bio, Inc. (NASDAQ: TRML) has announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). This board of leading experts will provide strategic guidance for the development of pacibekitug, Tourmaline's treatment for cardiovascular diseases. The CV SAB is expected to support Tourmaline as it advances towards potential Phase 3 clinical trial readiness in 2025.

The advisory board comprises academic and industry veterans with extensive experience in cardiovascular medicine, clinical trial design, and therapeutic innovation. Their expertise will be important in shaping the strategic direction of Tourmaline's cardiovascular program, including the ongoing TRANQUILITY Phase 2 clinical trial, for which topline data is expected in the first half of 2025.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotech company, has announced its participation in two upcoming investor conferences. CEO Sandeep Kulkarni is scheduled to present at:

• H.C. Wainwright 26th Annual Global Investor Conference in New York on September 9, 2024 at 12:00 pm ET
• Cantor Global Healthcare Conference in New York on September 17, 2024 at 3:40 pm ET

Both presentations will be available via live webcast on the company's website under the 'Events and Presentations' section. Replays will be archived on the site after each event. Tourmaline Bio focuses on developing transformative medicines for immune and inflammatory diseases.

Tourmaline Bio (NASDAQ: TRML) reported its Q2 2024 financial results and business highlights. Key points include:

• First patient dosed in Phase 2 TRANQUILITY trial for cardiovascular risk in May 2024
• On track to initiate Phase 3 trial for Thyroid Eye Disease (TED) in H2 2024
• Added to Russell 2000® and Russell 3000® Indexes in June 2024
• Cash position of $334.4 million as of June 30, 2024, providing runway into 2027
• Q2 2024 net loss of $17.5 million, or $0.68 per share
• R&D expenses increased to $15.7 million, G&A expenses rose to $6.2 million

The company continues to advance its clinical programs for pacibekitug in TED and cardiovascular diseases, with key data readouts expected in 2025.

Tourmaline Bio (NASDAQ: TRML) presented the design of its Phase 2 TRANQUILITY study at the American Society of Preventive Cardiology Congress 2024. The study evaluates TOUR006's ability to reduce high-sensitivity C-reactive protein (hs-CRP) in patients with chronic kidney disease (CKD) and elevated hs-CRP, who are at higher risk of atherosclerotic cardiovascular disease (ASCVD).

The trial involves 120 patients with CKD stage 3 or 4 and hs-CRP ≥2 and <15 mg/L, randomized to receive subcutaneous TOUR006 at various doses or placebo. The primary endpoint is the change in hs-CRP levels. Topline data is expected in the first half of 2025, potentially advancing TOUR006 toward Phase 3 readiness for ASCVD and other cardiovascular diseases.

Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson has been with Tourmaline since last summer and has served as the Interim CFO and Treasurer since October 2023. He played a key role in Tourmaline's growth, including a reverse merger in October 2023 and a $172.5 million public offering in January 2024. Robinson brings nearly 15 years of biotech finance and operations experience, having worked at Korro Bio, Jounce Therapeutics, and Merrimack Pharmaceuticals. He holds a B.S. in Management and an M.S. in Accounting from Boston College and is a CPA.

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.

Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, a monoclonal antibody targeting IL-6 to treat atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions. This randomized, double-blind, placebo-controlled trial involves patients with high inflammatory risk and chronic kidney disease. The trial aims to assess the drug's safety, pharmacokinetics, and pharmacodynamics, with results anticipated in the first half of 2025. If successful, TOUR006 could advance to Phase 3 by 2025, offering quarterly subcutaneous dosing and potentially positioning itself as a best-in-class treatment for ASCVD and related conditions.

Tourmaline Bio, Inc. reported its Q1 2024 financial results and recent business highlights. Initiatives include a Phase 2 trial for ASCVD and TED, a successful public offering, and $350.3 million in cash reserves. The company aims to improve the lives of patients with immune and inflammatory diseases.